CENTRAL GARDEN & PET CO
For the period ended Dec 27, 2025. Filed Feb 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 27, 2025 · Filed Feb 5, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-28; filed 2025-08-07.
0000887733-25-000032
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2025-12-27; filed 2026-02-05.
0000887733-26-000007
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 12 previous paragraphs and 12 current paragraphs.
9 unchanged; 3 reworded; 0 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 1 previous and 1 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Reworded paragraphs (3)
Previous wording
(1)In August 2019, our Board of Directors authorized a share repurchase program to purchase up to $100 million of our common stock (the "2019 Repurchase Authorization”), which authorization was fully utilized in the third quarter of fiscal 2025. In December 2024, our Board of Directors authorized a $100 million increase in the share repurchase program (the "2024 Repurchase Authorization"). The 2024 Repurchase Authorization has no fixed expiration date and expires when the amount authorized has been used or the Board withdraws its authorization. The repurchase of shares may be limited by certain financial covenants in our credit facility that restrict our ability to repurchase our stock. As of June 28, 2025, we had $46.5 million of authorization remaining under our 2024 Repurchase Authorization.
Current wording
(1)In December 2024, our Board of Directors authorized a $100 million increase in our share repurchase program (the "2024 Repurchase Authorization”). The 2024 Repurchase Authorization has no fixed expiration date and expires when the amount authorized has been used or the Board withdraws its authorization. The repurchase of shares may be limited by certain financial covenants in our credit facility that restrict our ability to repurchase our stock. As of December 27, 2025, we had $28.0 million of authorization remaining under our 2024 Repurchase Authorization.
Previous wording
(2)In February 2019, our Board of Directors authorized us to make supplemental stock purchases to minimize dilution resulting from issuances under our equity compensation plans (the “Equity Dilution Authorization”). In addition to our 2024 Repurchase Authorization, we are permitted to purchase annually a number of shares equal to the number of shares of restricted stock and stock options granted in the current fiscal year and the prior fiscal year, to the extent not already repurchased. The Equity Dilution Authorization has no fixed expiration date and expires when the Board withdraws its authorization.
Current wording
(2)In February 2019, our Board of Directors authorized us to make supplemental stock purchases to minimize dilution resulting from issuances under our equity compensation plans (the “Equity Dilution Authorization”). In addition to our regular share repurchase program, we are permitted to purchase annually a number of shares equal to the number of shares of restricted stock and stock options granted in the prior fiscal year, to the extent not already repurchased, and the current fiscal year. The Equity Dilution Authorization has no fixed expiration date and expires when the Board withdraws its authorization. There were 25,934 shares remaining under our Equity Dilution Authorization as of December 27, 2025.
Previous wording
(4)During the period, we repurchased 1,699,274 shares under the two programs: 1,131,014 CENTA shares and 568,260 CENT shares, including 8,191 shares repurchased under the Equity Dilution Authorization and 1,691,083 shares repurchased under the 2024 and 2019 Repurchase Authorizations.
Current wording
(4)During the period, we repurchased 660,302 CENTA shares under the 2024 Repurchase Authorization.